BACKGROUND: Distraction is used clinically to relieve and manage @entity158 . It is hypothesized that @entity158 demands attention and that exposure to another attention-demanding stimulus causes withdrawal of attention away from painful stimuli, thereby reducing perceived @entity158 . We have recently developed a @entity35 model that provides an opportunity to investigate the neurobiological mechanisms mediating distraction-induced @entity1337 , as these mechanisms are, at present, poorly understood. Given the well-described role of the endogenous cannabinoid (endocannabinoid; EC) system in the modulation of @entity158 and attentional processing, the present study investigated its role in distraction-induced antinociception in @entity35 . METHODS: Animals received the @entity13677 receptor antagonist/inverse agonist, @entity351 or vehicle intraperitoneally, 30   min prior to behavioural evaluation. @entity406 -evoked nociceptive behaviour was measured in the presence or absence of a novel-object distractor. Liquid chromatography-tandem mass spectrometry was used to determine the levels of the endogenous cannabinoids anandamide and @entity9394 ( @entity14512 ) in the ventral hippocampus (vHip). RESULTS: Exposure to a novel object distractor significantly reduced @entity406 -evoked nociceptive behaviour. The novel object-induced @entity10237 was attenuated by @entity351 . Novel object exposure was also associated with increased tissue levels of @entity9393 and 2-AG in the vHip. CONCLUSIONS: These data suggest that the reduction in @entity406 -evoked nociceptive behaviour that occurs as a result of exposure to a novel object may be mediated by engagement of the EC system, in particular in the vHip. The results provide evidence that the EC system may be an important neural substrate subserving attentional modulation of @entity158 .

Involvement of the endocannabinoid system in attentional modulation of nociceptive behaviour in XXXX .

@entity14512 :: ('CHEBI:52392', 'Chemical') :: ['2-AG'] @entity13677 :: ('25248(Tax:10116)', 'Gene') :: ['CB1'] @entity9394 :: ('MESH:C094503', 'Chemical') :: ['2-arachidonoylglycerol'] @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin', 'Formalin'] @entity9393 :: ('MESH:C078814', 'Chemical') :: ['anandamide'] @entity10237 :: ('MESH:D059226', 'Disease') :: ['reduction in nociceptive behaviour'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity351 :: ('MESH:C089032', 'Chemical') :: ['rimonabant']
@entity35 :: (10116,Species) :: ['rats']
